Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $96 from $72 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $112 from $72 at BMO Capital
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- M&A News: Protagonist Therapeutics Stock (PTGX) is Star of the Show on JNJ Bid Talk
- Protagonist Therapeutics rises 34.1%
- Midday Fly By: Trump threatens China tariffs, Kalshi valued at $5B